Proscia Concentriq vs Sectra Pathology
A reference lab heading into a vendor security review has the easier path with Proscia. It announced SOC 2 Type II in December 2025, holds ISO 27001 since October 2023, and a deployment page claims HIPAA alignment. Sectra's SOC 2 and HIPAA status is not stated, which makes it the harder sell to that security team.
Proscia's Concentriq AP-Dx has K230839 from February 2024 and K261380 from August 2026, the second adding the Leica Aperio GT 450 DX, cloud deployment and a predetermined change control plan. A pharma translational group can use the separate Life Sciences line for biomarker work. Agilent agreed to acquire Proscia for up to $270 million, and that deal has not closed.
Sectra suits a hospital group that wants pathology, radiology and genomics images in one viewer. Its Digital Pathology Module is cleared under K193054 and K232208, and the AI it offers comes from other vendors.
Pathology · Reviewed November 1, 2026
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
Sectra Pathology
by Sectra
Digital pathology image management (Sectra IDS7) with a marketplace for third-party AI apps. Sectra does not make the AI.
When to pick each one
Proscia Concentriq
- Two 510(k) records, latest adds Leica GT 450 DX
- SOC 2 Type II announced December 2025
- Life Sciences line for biopharma biomarker work
Sectra Pathology
- Pathology, radiology and genomics in one viewer
- Digital Pathology Module cleared March 2020 and April 2024
- Single contract for third-party AI apps
Score
Each row shows points earned of points available under the published rubric.
Proscia Concentriq
40of 100
Sectra Pathology
33of 100
| Dimension | Proscia Concentriq | Sectra Pathology | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 6 / 10 | 0 / 10 | +6 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 21 | 0 / 21 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Proscia Concentriq
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Demo request only. |
Sectra Pathology
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Contact form only. |
Evidence
Proscia Concentriq
FDA decisions
K261380 (opens in new tab)510(k)2026-08-05
Concentriq AP-Dx
K230839 (opens in new tab)510(k)2024-02-08
Concentriq Dx (marketed as Concentriq AP-Dx)
Sectra Pathology
FDA decisions
K232208 (opens in new tab)510(k)2024-04-16
Sectra Digital Pathology Module (Version 3.3)
K193054 (opens in new tab)510(k)2020-03-31
Sectra Digital Pathology Module
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Proscia Concentriq | Sectra Pathology |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | n/a | SE |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.